Finding the right time for weaning off immunosuppression in solid organ transplant recipients

Expert Review of Clinical Immunology

Volumn 6, Issue 6, 2010, Pages 879-892

  Orlando, Giuseppe ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

calcineurin inhibitors; immunosuppression; immunosuppression withdrawal; kidney transplantation; liver transplantation; quality of life; rejection; steroids; tolerance; weaning

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PREDNISONE; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; CHRONIC TOXICITY; CLINICAL OPERATIONAL TOLERANCE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SELECTIVITY; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HIGH RISK PATIENT; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LOW DRUG DOSE; ORGAN TRANSPLANTATION; PATIENT COMPLIANCE; QUALITY OF LIFE; REVIEW; SURVIVAL; TREATMENT OUTCOME;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BIOLOGICAL MARKERS; BIOMARKERS, PHARMACOLOGICAL; CLINICAL PROTOCOLS; GRAFT REJECTION; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; ORGAN TRANSPLANTATION; PATIENT COMPLIANCE; QUALITY OF LIFE; RISK ASSESSMENT;

EID: 78049448895     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.10.71     Document Type: Review

References (115)

1. Orlando G, Hematti P, Stratta RJ et al. Clinical operational tolerance after renal transplantation: current status and future challenges. Ann. Surg. (In Press) (2010).
2. Baiocchi L, Angelico M, De Luca L et al. Cyclosporine A versus tacrolimus monotherapy. Comparison on bile lipids in the frst three months after liver transplant in humans. Transpl. Int. 19(5), 12-18 (2006).
3. Lerut J, Mathys J, Verbaandert C et al. Tacrolimus monotherapy in liver transplantation: one-year results of a prospective, randomised, double-blind, placebo-controlled study Ann. Surg. 248(6), 956-967 (2008).
4. Sayegh M, Remuzzi G. Clinical update: immunosuppression minimisation. Lancet 369(9574), 1676-1678 (2007).
5. Hariharan S, Johnson CP, Bresnahan BA et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N. Engl. J. Med. 342(9), 605-612 (2000).
6. Burlingham WJ, Jankowska-Gan E, VanBuskirk A et al. Loss of tolerance to a maternal kidney transplant is selective for HLA class II: evidence from trans-vivo DTH and alloantibody analysis. Hum. Immunol. 61(12), 1395-1402 (2000).
7. Karam VH, Gasquet I, Delvart V et al. Quality of life in adult survivors beyond 10 years after liver, kidney, and heart transplantation. Transplantation 76(12), 1699-1704 (2003).
8. Galbraith CA, Hathaway D. Long-term effects of transplantation on quality of life. Transplantation 77(9 Suppl.), S84-S87 (2004).
9. Tisone G, Orlando G, Angelico M. Operational tolerance in clinical liver transplantation: emerging developments. Transpl. Immunol. 17(12), 108-113 (2007). (Pubitemid 46240887)
10. Orlando G, Soker S, Wood KJ. Clinical operational tolerance after liver transplantation. J. Hepatol. 50(6), 1247-1257 (2009).
11. Comerci GD, Williams TM, Kellie S. Immune tolerance after total lymphoid irradiation for heart transplantation: immunosuppressant-free survival for 8 years. J. Heart Lung Transpl. 28(7), 743-745 (2009).
12. Svendsen UG, Aggestrup S, Heilmann C et al. Transplantation of a lobe of lung from mother to child following previous transplantation with maternal bone marrow. Eur. Respir. J. 8, 334-337 (1995).
13. Starzl TE, Demetris AJ, Trucco M et al. Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology 17(6), 1127-1152 (1993).
14. Reyes J, Zeevi A, Ramos H et al. Frequent achievement of a drug-free state after orthotopic liver transplantation. Transplant. Proc. 25(6), 3315-3319 (1993).
15. Mazariegos GV, Ramos H, Shapiro R et al. Weaning of immunosuppression in long-term recipients of living related renal transplants: a preliminary study Transplant. Proc. 27(1), 207-209 (1995).
16. Ramos HC, Reyes J, Abu-Elmagd K et al. Weaning of immunosuppression in long-term liver transplant recipients. Transplantation 59(2), 212-217 (1995).
17. Mazariegos GV, Reyes J, Marino IR et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 63(2), 243-249 (1997).
18. Tzakis AG, Reyes J, Zeevi A et al. Early tolerance in pediatric liver allograft recipients. J. Pediatr. Surg. 29(6), 754-756 (1994).
19. Mazariegos GV, Sindhi R, Thomson AW, Marcos A. Clinical tolerance following liver transplantation: long term results and future prospects. Transpl. Immunol. 17(2), 114-119 (2007).
20. Thomson AW, Mazariegos GV, Reyes J et al. Monitoring the patient off immunosuppression. Conceptual framework for a proposed tolerance assay study in liver transplant recipients. Transplantation 72(8 Suppl.), S13-S22 (2001).
21. Mazariegos GV, Zahorchak AF, Reyes J et al. Dendritic cell subset ratio in peripheral blood correlates with successful withdrawal of immunosuppression in liver transplant patients. Am. J. Transplant. 3(6), 689-696 (2003).
22. Mazariegos GV, Zahorchak AF, Reyes J et al. Dendritic cell subset ratio in tolerant, weaning and non-tolerant liver recipients is not affected by extent of immunosuppression. Am. J. Transplant. 5(2), 314-322 (2005).
23. Tokita D, Mazariegos GV, Zahorchak AF et al. High PD-L1/CD86 ratio on plasmacytoid dendritic cells correlates with elevated T-regulatory cells in liver transplant tolerance. Transplantation 85(3), 369-377 (2008).
24. Devlin J, Doherty D, Thomson L et al. Defning the outcome of immunosuppression withdrawal after liver transplantation. Hepatology 27(4), 926-933 (1998).
25. Girlanda R, Rela M, Williams R et al. Long-term outcome of immunosuppression withdrawal after liver transplantation. Transplant. Proc. 37(4), 1708-1709 (2005). (Pubitemid 40790804)
26. VanBuskirk AM, Burlingham WJ, Jankowska-Gan E et al. Human allograft acceptance is associated with immune regulation. J. Clin. Invest. 106(1), 145-155 (2000).
27. Geissler F, Jankowska-Gan E, DeVito-Haynes LD et al. Human liver allograft acceptance and the 'tolerance assay': in vitro anti-donor T cell assays show hyporeactivity to donor cells, but unlike DTH, fail to detect linked suppression. Transplantation 72(4), 571-580 (2001).
28. Takatsuki M, Uemoto S, Inomata Y et al. Analysis of alloreactivity and intragraft cytokine profles in living donor liver transplant recipients with graft acceptance. Transpl. Immunol. 8(4), 279-286 (2001).
29. Takatsuki M, Uemoto S, Inomata Y et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 72(3), 449-454 (2001). (Pubitemid 32769631)
30. Koshiba T, Li Y, Takemura M et al. Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transpl. Immunol. 17(2), 94-97 (2007).
31. Li Y, Koshiba T, Yoshizawa A et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am. J. Transplant. 4(12), 2118-2125 (2004).
32. + regulatory T cells in operational tolerance after living donor liver transplantation. Transplant Proc. 37(1), 37-39 (2005).
33. Pons JA, Yélamos J, Ramírez P et al. Endothelial cell chimerism does not infuence allograft tolerance in liver transplant patients after withdrawal of immunosuppression. Transplantation 75(7), 1045-1047 (2003).
34. Tisone G, Orlando G, Cardillo A et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J. Hepatol. 44(4), 702-709 (2006).
35. Orlando G, Manzia T, Baiocchi L et al. The Tor Vergata weaning off immunosuppression trial in HCV liver transplant patients. The updated follow up at 78 months. Transpl. Immunol. 20(1-2), 43-47 (2008).
36. Gras J, Wieërs G, Vaerman JL et al. Early immunological monitoring after pediatric liver transplantation: cytokine immune deviation and graft acceptance in 40 recipients. Liver Transpl. 13(3), 426-433 (2007).
37. Hsu LW, Goto S, Nakano T et al. Immunosuppressive activity of serum taken from a liver transplant recipient after withdrawal of immunosuppressants. Transpl. Immunol. 17(2), 137-146 (2007).
38. Alexander SI, Smith N, Hu M et al. Chimerism and tolerance in a recipient of a deceased-donor liver transplant. N. Engl. J. Med. 358(4), 369-374 (2008).
39. Martínez-Llordella M, Lozano JJ, Puig-Pey I et al. Towards a diagnostic test of operational tolerance in liver transplantation employing transcriptional profling. J. Clin. Invest. 118(8), 2845-2857 (2008).
40. Martínez-Llordella M, Puig-Pey I, Orlando G et al. Multiparameter immune profling of operational tolerance in liver transplantation. Am. J. Transpl. 7(2), 309-319 (2007).
41. Pons JA, Ramírez P, Revilla-Nuin B et al. Immunosuppression withdrawal improves long-term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients. Clin. Transplant. 23(3), 329-336 (2009).
42. Pons JA, Revilla-Nuin B, Baroja-Mazo A et al. FoxP3 in peripheral blood is associated with operational tolerance in liver transplant patients during immunosuppression withdrawal. Transplantation 86(10), 1370-1378 (2008).
43. Girnita A, Mazariegos GV, Castellaneta A et al. Liver transplant recipients weaned off immunosuppression lack circulating donor-specifc antibodies. Hum. Immunol. 71(3), 274-276 (2010).
44. Lee JH, Lee SK, Lee HJ et al. Withdrawal of immunosuppression in pediatric liver transplant recipients in Korea. Yonsei Med. J. 50(6), 784-788 (2009).
45. Yoshitomi M, Koshiba T, Haga H et al. Requirement of protocol biopsy before and after complete cessation of immunosuppression after liver transplantation. Transplantation 87(4), 606-614 (2009).
46. Li Y, Zhao X, Cheng D et al. The presence of Foxp3 expressing T cells within grafts of tolerant human liver transplant recipients. Transplantation 86(12), 1837-1843 (2008).
47. Assy N, Adams PC, Myers P et al. Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid. Transplantation 83(12), 1571-1576 (2007). (Pubitemid 46987908)
48. Assy N, Adams PC, Myers P et al. A randomised controlled trial of total immunosuppression withdrawal in stable liver transplant recipients. Gut 56(2), 304-306 (2007).
49. Matthes-Martin S, Peters C, Königsrainer A et al. Successful stem cell transplantation following orthotopic liver transplantation from the same haploidentical family donor in a girl with hemophagocytic lymphohistiocytosis. Blood 96(12), 3997-3999 (2000).
50. Mellgren K, Fasth A, Saalman R et al. Liver transplantation after stem cell transplantation with the same living donor in a monozygotic twin with acute myeloid leukemia. Ann. Hematol. 84(11), 755-757 (2005).
51. Donckier V, Troisi R, Toungouz M et al. Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft. Transpl. Immunol. 13(2), 139-146 (2004).
52. Donckier V, Troisi R, Le Moine A et al. Early immunosuppression withdrawal after living donor liver transplantation and donor stem cell infusion. Liver Transpl. 12(10), 1523-1528 (2006).
53. Craciun L, Stordeur P, Troisi R et al. A rapid test of alloreactivity based on interleukin-2 mRNA expression might identify liver transplant recipients with donor-specifc hyporesponsiveness. Transplant Proc. 39(8), 2665-2667 (2007).
54. Tryphonopoulos P, Tzakis AG, Weppler D et al. The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation. Am. J. Transplant. 5(3), 608-613 (2005).
55. Urban CH, Deutschmann A, Kerbl R et al. Organ tolerance following cadaveric liver transplantation for chronic graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant. 30(8), 535-537 (2002).
56. Kadry Z, Mullhaupt B, Renner EL et al. Living donor liver transplantation and tolerance: a potential strategy in cholangiocarcinoma. Transplantation 76(6), 1003-1006 (2003).
57. Andreoni KA, Lin JI, Groben PA. Liver transplantation 27 years after bone marrow transplantation from the same living donor. N. Engl. J. Med. 350(25), 2624-2625 (2004).
58. Eason JD, Cohen AJ, Nair S et al. Tolerance: is it worth the risk? Transplantation 79(9), 1157-1159 (2005).
59. Starzl TE, Murase N, Abu-Elmagd K et al. Tolerogenic immunosuppression for organ transplantation. Lancet 361(9368), 1502-1510 (2003).
60. Starzl TE, Zinkernagel RM. Antigen localization and migration in immunity and tolerance. N. Engl. J. Med. 339(26), 1905-1913 (1998).
61. Starzl TE, Zinkernagel RM. Transplantation tolerance from a historical perspective. Nat Rev. Immunol. 1(3), 233-239 (2001).
62. Spitzer TR, Delmonico F, Tolkoff-Rubin N et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 68(4), 480-484 (1999).
63. Bühler LH, Spitzer TR, Sykes M et al. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation 74(10), 1405-1409 (2002).
64. Fudaba Y, Spitzer TR, Shaffer J et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am. J. Transplant. 6(9), 2121-2133 (2006).
65. Kawai T, Cosimi AB, Spitzer TR et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N. Engl. J. Med. 358(4), 353-361 (2008).
66. Millan MT, Shizuru JA, Hoffmann P et al. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation 73(9), 1386-1391 (2002).
67. Scandling JD, Busque S, Dejbakhsh-Jones S et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N. Engl. J. Med. 358(4), 362-368 (2008).
68. Lerut J, Bonaccorsi-Riani E, Finet P, Gianello P. Minimization of steroids in liver transplantation. Transpl. Int. 22(1), 2-19 (2009).
69. Adam R, Lucidi V, Karam V. Liver transplantation in Europe: is there a room for improvement? J. Hepatol. 42(1), 33-40 (2005).
70. Strober S, Lowsky RJ, Shizuru JA et al. Approaches to transplantation tolerance in humans. Transplantation 77(6), 932-936 (2004).
71. Farkas SA, Schnitzbauer AA, Kirchner G et al. Calcineurin inhibitor minimization protocols in liver transplantation. Transpl. Int. 22(1), 49-60 (2009).
72. Neuberger JM, Mamelok RD, Neuhaus P et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am. J. Transplant. 9(2), 327-323 (2009).
73. Padbury RT, Gunson BK, Dousset B et al. Steroid withdrawal from long-term immunosuppression in liver allograft recipients. Transplantation 55(4), 789-794 (1993).
74. Padbury RT, Attard A, Mirza DF et al. Extended preservation of the liver with UW solution-is it justifable? Transplantation 57(10), 1490-1493 (1994).
75. + T cells in kidney operational tolerance transplanted individuals. Hum. Immunol. 71(5), 442-450 (2010).
76. Owens ML, Maxwell G, Goodnight J, Wolcott MW. Discontinuance of immunosuppression in renal transplant patients. Arch. Surg. 110(12), 1450-1451 (1975).
77. Zoller KM, Cho SI, Cohen JJ, Harrington JT. Cessation of immunosuppressive therapy after successful transplantation: a national survey Kidney Int. 18(1), 110-114 (1980).
78. Najarian JS. Editorial comment. Arch. Surg. 110(5), 1451 (1975).
79. Hussey JL. Letter to: discontinuance of immunosuppression. Arch. Surg. 111(5), 614 (1975).
80. Uehling DT, Hussey JL, Weinstein AB et al. Cessation of immunosuppression after renal transplantation. Surgery 79(3), 278-282 (1976).
81. Van Buskirk AM, Burlingham WJ, Jankowska-Gan E et al. Human allograft acceptance is associated with immune regulation. J. Clin. Invest. 106(1), 145-155 (2000).
82. low adaptive T regulatory cells suppress delayed-type hypersensitivity during transplant tolerance. J. Immunol. 178(6), 3983-3995 (2007).
83. Fischer T, Schobel H, Barenbrock M. Specifc immune tolerance during pregnancy after renal transplantation. Eur. J. Obst. Gyn. 70(2), 217-219 (1996).
84. Roussey-Kesler G, Giral M, Moreau A et al. Clinical operational tolerance after kidney transplantation. Am. J. Transpl. 6(4), 736-746 (2006).
85. Ballet C, Roussey-Kesler G, Aubin JT et al. Humoral and cellular responses to infuenza vaccination in human recipients naturally tolerant to a kidney allograft. Am. J. Transpl. 6(11), 2796-2801 (2006).
86. +T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation 81(3), 398-407 (2006).
87. + lymphocyte populations in long-term drug-free tolerance and chronic rejection in human kidney graft recipients. J. Am. Soc. Nephrol. 17(1), 294-304 (2006).
88. Brouard S, Dupont A, Giral M et al. Operationally tolerant and minimally immunosuppressed kidney recipients display strongly altered blood T-cell clonal regulation. Am. J. Transplant. 5(2), 330-340 (2005).
89. Braudeau C, Ashton-Chess J, Giral M et al. Contrasted blood and intragraft toll-like receptor 4 mRNA profles in operational tolerance versus chronic rejection in kidney transplant recipients. Transplantation 86(1), 130-136 (2008).
90. Brouard S, Mansfeld E, Braud C et al. Identifcation of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc. Natl Acad. Sci. USA 104(39), 15448-15453 (2007).
91. Braud C, Baeten D, Giral M et al. Immunosuppressive drug-free operational immune tolerance in human kidney transplant recipients: Part I. Blood gene expression statistical analysis. J. Cell Biochem. 103(6), 1681-1692 (2008). (Pubitemid 351501902)
92. Sivozhelezov V, Braud C, Giacomelli L et al. Immunosuppressive drug-free operational immune tolerance in human kidney transplants recipients. Part II. Non-statistical gene microarray analysis. J. Cell Biochem. 103(6), 1693-1706 (2008). (Pubitemid 351501903)
93. Newell KA, Asare A, Kirk AD et al. Identifcation of a B cell signature associated with renal transplant tolerance in humans. J. Clin. Invest. 120(6), 1836-1847 (2010).
94. Sagoo P, Perucha E, Sawitzki B et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J. Clin. Invest. 120(6), 1848-1861 (2010).
95. Christensen LL, Grunnet N, Rüdiger N et al. Indications of immunological tolerance in kidney transplantation. Tissue Antigens 51(6), 637-644 (1998).
96. Sayegh MH, Fine NA, Smith JL et al. Immunologic tolerance to renal allografts after bone marrow transplants from the same donors. Ann. Int. Med. 114(11), 954-955 (1991).
97. Helg C, Chapuis B, Bolle JF et al. Renal transplantation without immunosuppression in a host with tolerance induced by allogeneic bone marrow transplantation. Transplantation 58(12), 1420-1422 (1994).
98. Jacobsen N, Taaning E, Ladefoged J et al. Tolerance to an HLA-B,DR disparate kidney allograft after bone-marrow transplantation from same donor. Lancet 343(8900), 800 (1994).
99. Sorof JM, Koerper MA, Portale AA et al. Renal transplantation without chronic immunosuppression after T cell-depleted, HLA-mismatched bone marrow transplantation. Transplantation 59(11), 1633-1635 (1995).
100. Butcher JA, Hariharan S, Adams MB et al. Renal transplantation for end-stage renal disease following bone marrow transplantation: a report of six cases, with and without immunosuppression. Clin. Transplant. 13(4), 330-335 (1999).
101. Sellers MT, Deierhoi MH, Curtis JJ et al. Tolerance in renal transplantation after allogeneic bone marrow transplantation-6-year follow-up. Transplantation 71(11), 1681-1683 (2001).
102. Strober S, Dhillon M, Schubert M et al. Acquired immune tolerance to cadaveric renal allografts. A study of three patients treated with total lymphoid irradiation. N. Engl. J. Med. 321(1), 28-33 (1989).
103. Strober S, Benike C, Krishnaswamy S et al. Clinical transplantation tolerance twelve years after prospective withdrawal of immunosuppressive drugs: studies of chimerism and anti-donor reactivity Transplantation 69(8), 1549-1554 (2000).
104. Hutchinson JA, Brem-Exner BG, Riquelme P et al. A cell-based approach to the minimization of immunosuppression in renal transplantation. Transpl. Int. 21(8), 742-754 (2008).
105. Hutchinson JA, Riquelme P, Brem-Exner BG et al. Transplant acceptance-inducing cells as an immune-conditioning therapy in renal transplantation. Transpl. Int. 21(8), 728-741 (2008).
106. Danger R, Giral M, Soulillou JP, Brouard S. Rationale and criteria of eligibility for calcineurin inhibitor interruption following kidney transplantation. Curr. Opin. Organ Transplant. 13(6), 609-613 (2008).
107. Haller M, Oberbauer R. Calcineurin inhibitor minimization, withdrawal and avoidance procotols after kidney transplantation. Transpl. Int. 22(6), 69-77 (2009).
108. Ekberg H, Grinyó J, Nashan B et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR study Am. J. Transplant. 7(3), 560-570 (2007).
109. Anjum S, Andany MA, McClean JC et al. Defning the risk of elective cyclosporine withdrawal in stable kidney transplant recipients. Am. J. Transplant. 2(2), 179-185 (2002).
110. Abramowicz D, Del Carmen Rial M, Vitko S et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a fve-year, prospective, randomized study J. Am. Soc. Nephrol. 16(7), 2234-2240 (2005).
111. Hazzan M, Labalette M, Copin MC et al. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. J. Am. Soc. Nephrol. 16(8), 2509-2516 (2005).
112. Hazzan M, Buob D, Labalette M et al. Assessment of the risk of chronic allograft dysfunction after renal transplantation in a randomized cyclosporine withdrawal trial. Transplantation 82(5), 657-662 (2006).
113. Pascual J, Bloom D, Torrealba J et al. Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells. Am. J. Transplant. 8(7), 1529-1536 (2008).
114. Matas AJ. Minimization of steroids in kidney transplantation. Transpl. Int. 22(1), 38-48 (2009).
115. Li L, Chang A, Naesens M et al. Steroid-free immunosuppression since 1999: 129 pediatric renal transplants with sustained graft and patient benefts. Am. J. Transplant. 9(6), 1362-1372 (2009).